Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE.
We investigated the mechanism whereby protein Fv (pFv), a human sialoprotein found in normal liver and largely released in the intestinal tract in patients with viral hepatitis, induces mediator release from basophils and mast cells and evaluated whether it also induces IL-4 synthesis and secretion in basophils. pFv is a potent stimulus for histamine and IL-4 release from purified basophils. Histamine and IL-4 secretion from basophils activated by pFv was significantly correlated (rs = 0.70; p < 0.001). There was also a correlation (rs = 0.58; p < 0.01) between the maximum pFv- and anti-IgE-induced IL-4 release from basophils. The average t1/2 for pFv-induced histamine release was lower (3.5+/-1.5 min) than for IL-4 release (79.5+/-8.5 min; p < 0.01). IL-4 mRNA, constitutively present in basophils, was increased after stimulation by pFv and was inhibited by cyclosporin A and tacrolimus. Basophils from which IgE had been dissociated by brief exposure to lactic acid no longer released IL-4 in response to pFv and anti-IgE. The response to an mAb cross-linking the alpha-chain of Fc epsilon RI was unaffected by this treatment. Three human VH3+ monoclonal IgM concentration-dependently inhibited pFv-induced secretion of IL-4 and histamine from basophils and of histamine from human lung mast cells. In contrast, VH6+ monoclonal IgM did not inhibit the release of IL-4 and histamine induced by pFv. These results indicate that pFv, which acts as an endogenous superallergen, interacts with the VH3 domain of IgE to induce the synthesis and release of IL-4 from human Fc epsilon RI+ cells.
Patella
V
V
Division of Clinical Immunology and Allergy, University of Naples Federico II, Italy.
Giuliano
A
A
Bouvet
J P
JP
Marone
G
G
D000328:Adult; D000485:Allergens / Q000502:physiology; D000888:Antibodies, Anti-Idiotypic / Q000502:physiology; D001491:Basophils / Q000187:drug effects / Q000378:metabolism; D016572:Cyclosporine / Q000494:pharmacology; D006636:Histamine Release / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D007143:Immunoglobulin Heavy Chains / Q000378:metabolism* / Q000502:physiology; D007075:Immunoglobulin M / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000378:metabolism* / Q000502:physiology; D015847:Interleukin-4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D007700:Kinetics; D019344:Lactic Acid / Q000494:pharmacology; D008168:Lung; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism; D009194:Myeloma Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D017455:Receptors, IgE / Q000032:analysis*; D012795:Sialoglycoproteins / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D018089:Superantigens / Q000378:metabolism / Q000502:physiology*; D016559:Tacrolimus / Q000494:pharmacology
D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; C089422:Fv protein, human; D007143:Immunoglobulin Heavy Chains; D007075:Immunoglobulin M; D007135:Immunoglobulin Variable Region; D008222:Lymphokines; D009194:Myeloma Proteins; D012333:RNA, Messenger; D017455:Receptors, IgE; D012795:Sialoglycoproteins; D018089:Superantigens; C026408:anti-IgE antibodies; D015847:Interleukin-4; D019344:Lactic Acid; D007073:Immunoglobulin E; D016572:Cyclosporine; D016559:Tacrolimus